G-CSF immunotherapy for treatment of acute disseminated murine melioidosis

FEMS Microbiology Letters

Volumn 224, Issue 2, 2003, Pages 315-318

  Powell, Kellie ^a   Ulett, Glen ^b   Hirst, Robert ^a   Norton, Robert ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Granulocyte colony stimulating factor; Melioidosis; Murine model

Indexed keywords

CEFTAZIDIME; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; IMMUNOTHERAPY; MELIOIDOSIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA PSEUDOMALLEI; MURINAE;

EID: 0042208059     PISSN: 03781097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1097(03)00473-7     Document Type: Article

References (14)

1. Wuthiekanun V., Smith M.D., Dance D.A.B., White N.J. Isolation of Pseudomonas pseudomallei from soil in north-eastern Thailand. Trans. R. Soc. Trop. Med. Hyg. 89:1995;41-43.
2. Currie, B.J. (2000) Melioidosis: An Australian Perspective of an Emerging Infectious Disease. Recent Advances in Microbiology, Vol. 8, pp. 1-75. The Australian Society of Microbiology, Melbourne.
3. Hirst R.G., Indriana J., Cocciolone R.A. An introduction to melioidosis. Innate resistance and acquired immunity to Pseudomonas pseudomallei. Aust. Biol. 5:1992;203-213.
4. Chaowagul W., Suputtamongkol Y., Dance D.A.B., Rajchanuvong A., Pattara-arechachai J., White N.J. Relapse in Melioidosis: Incidence and risk factors. J. Infect. Dis. 168:1993;1181-1185.
5. White N.J., Dance D.A.B., Chaowagul W., Wattanagoon Y., Wuthiekanun V., Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet. 2:1989;697-701.
6. Leakey A.K., Ulett G.C., Hirst R.G. BALB/c and C57BL/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animals models for the acute and chronic forms of human melioidosis. Microb. Pathog. 24:1998;269-275.
7. Ulett G.C., Ketheesan N., Hirst R.G. Macrophage-lymphocyte interactions mediate anti-Burkholderia pseudomallei activity. FEMS Immunol. Med. Microbiol. 21:1998;283-286.
8. Ulett G.C., Hirst R., Bowden B., Powell K., Norton R. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. J. Antimicrob. Chem. 51:2003;77-81.
9. Root R.K., Dale D.C. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections of nonneutropenic patients. J. Infect. Dis. 179:1999;S342-S352.
10. Lieschke G.J., Burgess A.W. Granulocyte colony stimulating factor and granulocyte-macrophage colony-stimulating factor. N. Engl. J. Med. 327:1992;28-35.
11. Nelson S., Heyder A.M., Stone J., et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumomia. J. Infect. Dis. 182:2000;970-973.
12. Miura E., Procianoy R.S., Bittar C., et al. A randomized double-masked, placebo controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early onset sepsis. Pediatrics. 107:2001;30-35.
13. Stephens D.P., Fisher D.A., Currie B.J. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern. Med. J. 32:2002;143.
14. Barsig J., Bundschuh D.S., Hartung T., Bauhofer A., Sauer A., Wendel A. Control of fecal peritoneal infection in mice by colony-stimulating factors. J. Infect. Dis. 174:1996;790-799.